Market cap
$2,262 Mln
Revenue (TTM)
$65 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 0.00 | 1,526.81 | 1,053.16 | 104.39 | 32.03 |
| EBIT | 0.00 | -41.71 | -37.78 | -0.81 | 6.08 |
| Net Profit | 0.00 | 16.21 | 8.69 | -4.24 | 0.75 |
| EPS | 0.00 | 25.92 | 19.37 | 11.75 | 9.54 |
| Book Value | -- | -- | -6.24 | -6.18 | -13.30 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Jun-26 | Jun-25 | Jun-24 |
| EBIT-Margin
| -723.88 | -768.97 | -- | -465.51 | -982.24 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -15.58 | -16.01 | -9.86 | -18.95 | -17.91 |
| Return on Capital
| -12.92 | -13.26 | -8.89 | -15.42 | -14.45 |
| Return on Assets
| -11.53 | -11.97 | -7.38 | -14.05 | -13.14 |
| Debt to Equity (x)
| -- | -- | -- | 0.21 | 0.25 |
Profitability
ROCE
-8.89
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
-8.89
|
-15.42
|
-14.45
|
-13.40
|
-14.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-9.86
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
-9.86
|
-18.95
|
-17.91
|
-16.40
|
-16.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-7.38
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
-7.38
|
-14.05
|
-13.14
|
-12.30
|
-12.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
--
|
-465.51
|
-982.24
|
-835.32
|
-792.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-47.82
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
-47.82
|
-593.92
|
-1,490.27
|
-1,091.71
|
-894.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
5.99
--
Year on year growth in net sales
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
5.99
|
1.91
|
-0.21
|
-0.27
|
0.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
--
|
-38.10
|
7.48
|
22.60
|
8.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
43.71
--
Year on year growth in profit after tax
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
43.71
|
-16.13
|
-7.41
|
10.35
|
7.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.45
--
Year on year growth in earnings per share
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
0.45
|
-0.02
|
0.10
|
0.38
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
--
|
0.21
|
0.25
|
0.23
|
0.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
--
|
0.10
|
0.03
|
0.02
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.43
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
2.43
|
1.99
|
1.18
|
1.95
|
1.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
2.09
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
2.09
|
1.77
|
1.18
|
2.05
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
--
|
-3.49
|
-2.81
|
-3.22
|
-4.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
47.46
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
47.46
|
86.44
|
355.00
|
93.29
|
43.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.15
--
Sales / Average Total Assets
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
0.15
|
0.02
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
109.26
--
Average Debtors / Sales * 365
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
109.26
|
380.35
|
864.85
|
277.58
|
160.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
551.78
--
Average Inventory / Sales * 365
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
551.78
|
791.94
|
-19.23
|
-28.76
|
-1.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
587.20
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
587.20
|
931.00
|
121.02
|
143.73
|
122.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
73.83
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
73.83
|
241.30
|
724.61
|
105.09
|
36.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-30.40
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
-30.40
|
-13.58
|
-8.69
|
-4.50
|
-1.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
3.08
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
3.08
|
2.32
|
1.59
|
0.73
|
0.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
--
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Jun-26
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
|---|---|---|---|---|---|
|
Mesoblast - ADR
|
--
|
-18.38
|
-14.63
|
-7.07
|
-2.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|